Abstract
Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.
| Original language | English |
|---|---|
| Pages (from-to) | 71-80 |
| Number of pages | 10 |
| Journal | American Journal of Drug and Alcohol Abuse |
| Volume | 33 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2007 |
Bibliographical note
Funding Information:This study was supported by the National Institute on Nursing Research (R01 NR009478) and the National Institute on Drug Abuse (R01 DA15022).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adherence
- Clinical trial
- HCV
- HIV
- Injection drug user
- Minority
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Clinical Psychology
- Psychiatry and Mental health
Fingerprint
Dive into the research topics of 'Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver